 |
  
Biotech Jobs, Learning Resources, Career Tools
|
|
| ||||||||||||||||||||||||||||||
|  |  iCell Therapeutics Receives Support From the National Research Council's Industrial Research Assistance Program for Development of Cancer TreatmentPress Release October 10, 2005 VANCOUVER, British Columbia, Oct. 10 /PRNewswire/ -- iCell Therapeutics is pleased to announce that it has received support from the National Research Council of Canada's - Industrial Research Assistance P rogram (NRC-IRAP) for development of the company's LDE-TTX technology for treatment of Cancer. NRC-IRAP's contribution will support the scale up and pre-clinical development of iCell's LDE-TTX drug candidate. iCell has already completed several successful pre-clinical and clinical trials in Brazil which have demonstrated the safety of LDE-TTX. The National Research Council approved iCell's application following an in depth familiarization with the LDE Technology and iCell's products, and a review of the Company's organizational and fiscal capability to carry on with the proposed program. "The involvement of the NRC-IRAP in contributing to our scientific program will be fundamental in assisting us to bridge the financial needs associated with our drive towards commercialization of iCell's technologies. IRAP's support will allow the company to proceed more rapidly towards initiating clinical trials in North America," said Kito Tosetti, CEO and President of iCell Therapeutics. The total amount of NRC-IRAP's contribution for this program amounts to $219,998. About NRC-IRAP The National Research Council-Industrial Research Assistance Program (NRC-IRAP) is Canada's premier innovation assistance program for small and medium-sized enterprises (SMEs). It is a vital component of the NRC, a cornerstone in Canada's innovation system, regarded world-wide as one of the best programs of its kind. NRC-IRAP's mandate -- to stimulate wealth creation for Canada through technological innovation -- is largely accomplished by providing technology assistance to SMEs at all stages of the innovation process, to build their innovation capacity. NRC-IRAP helps SMEs understand the technology issues and opportunities and provides linkages to the best expertise in Canada. About iCell Therapeutics iCell Therapeutics is a dynamic biotechnology company dedicated to establishing new standards of care in oncology and cardiovascular treatments. iCell's proprietary site selective Low Density Emulsion (LDE) technology and products are backed by more than 16 years of research. The technology is validated by extensive pre-clinical animal and clinical studies. These studies have generated an array of new product candidates for cancer and cardiovascular diseases. The company's successful achievement of all key milestones planned in its 2005 research and development program has created the foundations to its methodological progress towards worldwide commercialization of its targeted chemotherapies and set the ground floor opportunity for a high value investment. For more information contact Ali Ardakani, Director of Corporate Development iCell Therapeutics Inc 604-922-3827 info@icelltherapeutics.com www.icelltherapeutics.com Source: iCell Therapeutics Inc Web site: http://www.icelltherapeutics.com/
About hireBio
::
Copyright ::
Privacy
:: Legal
:: Contact |
 |
|
 |
Print
This Page